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Recessive Mutations in COL25A1 Are a Cause of
Congenital Cranial Dysinnervation Disorder
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Mohamad Alanazi,5 Asma Tahir,1 Coralie Poizat,3 and Nada Al Tassan1,*
Abnormal ocular motility is a common clinical feature in congenital cranial dysinnervation disorder (CCDD). To date, eight genes
related to neuronal development have been associated with different CCDD phenotypes. By using linkage analysis, candidate gene
screening, and exome sequencing, we identified three mutations in collagen, type XXV, alpha 1 (COL25A1) in individuals with auto-
somal-recessive inheritance of CCDD ophthalmic phenotypes. These mutations affected either stability or levels of the protein. We
further detected altered levels of sAPP (neuronal protein involved in axon guidance and synaptogenesis) and TUBB3 (encoded by
TUBB3, which is mutated in CFEOM3) as a result of null mutations in COL25A1. Our data suggest that lack of COL25A1 might interfere
with molecular pathways involved in oculomotor neuron development, leading to CCDD phenotypes.Congenital cranial dysinnervation disorders (CCDDs) are a
heterogeneous group of neurogenic syndromes of the
ocular muscle and facial innervation; the mutated genes
influence brainstem and cranial nerve development.1
Most CCDDs present with abnormal ocular motility; these
include congenital fibrosis of the extraocular muscles type
1, 2, and 3 (CFEOM1 [MIM 135700], CFEOM2 [MIM
602078], and CFEOM3 [MIM 600638]), HOXA1 spectrum
(MIM 142955), horizontal gaze palsy with progressive
scoliosis (HGPPS [MIM 607313]), Duane retraction syn-
drome (DRS [MIM 126800]), and Moebius syndrome
(MBS [MIM 157900]).2–7
Mutations in different genes contribute to CCDD etiol-
ogy by affecting neuronal development. Expressions of
certain genes influence the development of the cranial
nerves through molecular events including the cytoskel-
eton microtubule dynamics and axon path guidance. In
CFEOM1, dominant mutations in KIF21A (MIM 608283)
alter the kinesin microtubule-associated protein that nor-
mally inhibits microtubule growth inside the cell and di-
rects axon growth toward the oculomotor muscles.3 There
is probably a recessive cause for CFEOM1 that is yet to be
determined.8 Complete loss of the oculomotor nerves for
both eyes occur in CFEOM2, where homozygous muta-
tions in the homeodomain transcription factor (PHOX2A
[MIM 602753]) affect the survival of the oculomotor and
trochlear motor neurons during development.9 Retinal
dysfunction is also part of the CFEOM2 phenotype.10 In
CFEOM3 and rarely in CFEOM1, heterozygous mutations
in the cytoskeletal network gene known as neuron-specific
component b-tubulin III (TUBB3 [MIM 602661]) underlie
the phenotype; the encoded protein interacts with kinesin
and influences guidance of the cranial nerves.11 Rare cases1Department of Genetics, Research Center, King Faisal Specialist Hospital and
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The Amerof CFEOM3 can also be caused by heterozygous mutations
in KIF21A.12 One of the most common CCDD phenotypes
is DRS, which typically presents with lack of abduction,
adduction constraint, globe retraction, and palpebral
fissure narrowing on attempted adduction.13 Although
most cases of DRS are idiopathic and not familial, muta-
tions in CHN1 (MIM 118423) were identified in families
with dominant DRS. This gene plays a role in abducens
and oculomotor nerve development by controlling ocular
motor axon path-finding mechanisms.14 Homozygous
mutations in HOXA1 (MIM 142955) were identified in in-
dividuals with bilateral DRS associated with hearing and
cardiovascular abnormalities,5 and mutations in ROBO3
(MIM 608630), which encodes an axon guidance mole-
cule, lead to autosomal-recessive HGPPS.15 Recessive muta-
tions in ECEL1 (MIM 605896), a gene that might play a
role in neuromuscular junction formation, cause CCDD
phenotypes in the setting of arthrogryposis.10 Despite
the genetic heterogeneity that might explain these vari-
able phenotypes, mutations in common CCDD genes do
not underlie common forms of incomitant strabismus.16
We identified a consanguineous Saudi family with four
children, three of whom were affected by CCDD, congen-
ital ptosis, or DRS. The proband (II.1) presented with right
congenital ptosis covering the upper half of the pupil. His
sister (II.2) had bilateral congenital ptosis covering the up-
per half of the pupil, and his affected brother (II.3) had no
ptosis but presented with bilateral DRS (exotropic form in
the right eye, esotropic form in the left eye). The fourth
male sibling had a completely normal ophthalmic exami-
nation, as did both parents. DNA was extracted from
parents and all affected and unaffected children after
obtaining informed consent according to the institutionalResearch Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia; 2Division of
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rules and regulations (KFSHRC RAC # 2080020, KKESH
0424-P). To determine the underlying genetic defect in
this family, we first sequenced all coding exons of
KIF21A, PHOX2A, HOXA1, TUBB3, and ROBO3. No coding
or splice site pathogenic mutations were identified in these
genes.
After excluding mutations in the reported candidate
genes as a possible genetic cause for CCDD in this family,
we proceeded with linkage analysis by Affymetrix Gene-
Chip Human Mapping 250K. Multipoint linkage analysis
assuming an autosomal-recessive mode of inheritance17
detected a potential disease locus on chromosome
4q24–25 with a maximum logarithm of odds (LOD) score
of 2.5. Candidate genes in the 5.12 Mb linkage region
were prioritized with suspects software,18 and the entire
open reading frames (ORFs) for 18 of the 30 annotated
genes in the region were amplified and sequenced (Table
S1, Figure S1 available online). Subsequent analysis of
sequencing data revealed a homozygous missense muta-
tion in exon 21 of COL25A1 (c.1144G>A, RefSeq accession
number NM_198721.3) leading to a p.Gly382Arg substitu-
tion in the encoded protein (primers listed in Table S2).
This mutation cosegregated with the phenotype in family
A in an autosomal-recessive manner and was absent in 500
ethnically matched normal control subjects. Based on this
finding, COL25A1 exons were screened in 41 single CCDD
case subjects; several known and unknown variants were
identified in COL25A1 including 33 intronic variants, 3
synonymous polymorphisms, and 1 nonsynonymous
variant (Table S3). Only one heterozygous nonsense muta-
tion in exon 28 (c.1489G>T) was identified in a single
nonfamilial case (DRSA1) that presented with exotropic
DRS. This mutation, which is predicted to result in a pre-
mature stop codon (p.Gly497Ter), was also present in his
unaffected brother DRSA2. To position another disease
locus in this case, representative regions of COL25A1 pro-
moter were sequenced and CNV analysis was conducted
for both siblings via the Affymetrix GeneChip Mapping
6.0 kit. Analysis was performed with the Affymetrix
Genotyping Console (v.3.01) against ethnically matched
normal control subjects. No mutations were detected in
the promoter region but a heterozygous CNV deletion of
12.4 kb spanning exons 4–10 of COL25A1 (chr4:
109,852,901–109,976,457, UCSC GRCh37/hg19, Fig-
ure S2) was identified in the affected DRSA1 individual,
and this CNV was absent in the unaffected sibling. The
origins of the CNV deletion could not be determined
because DNA from parents was unavailable for analysis.
Next we preformed whole-exome sequencing with Sure-
Select Human All Exon kit and Illumina HiSeq 2000
Sequencer (Illumina) on the proband from family A and
the affected single case subject DRSA1. The resulting vari-
ants in the linkage region were filtered as homozygous
(coding or splicing) in the identified linkage region (het-
erozygous in the single case) and absent in the dbSNP data-
base (GRCh37) and 1000 Genomes database. Analysis
confirmed the presence of the homozygous c.1144G>A148 The American Journal of Human Genetics 96, 147–152, January 8and the heterozygous c.1489G>T mutations and the
absence of other pathogenic mutations in the linkage
region and in genes involved in overlapping pheno-
types including previously identified DRS and hereditary
congenital ptosis related loci/genes: SALL4 (MIM
607343),19 CHN1,14 PTOS1 (MIM 178300),20 ZFHX4
(MIM 606940),21 TUBB2B (MIM 612850),22 and HOXB1
(MIM 142968).23
Collagen, type XXV, alpha 1 (COL25A1) encodes a trans-
membrane protein that consists of an N-terminal intracel-
lular noncollagenous domain, a transmembrane domain,
and three extracellular collagen-like domains separated
by four noncollagenous domains. The collagen-like do-
mains contain unique repetitive patterns (Gly-X-Y) that
stabilize the triple helix. Proteolytic cleavage of COL25A1
by furin convertase produces a soluble form known as
collagen-like amyloidogenic component (sCLAC).24,25
sCLAC folds into a protease-resistant triple helical mole-
cule that binds fibrillized amyloid beta (Abeta) and further
assembles amyloid fibrils into protease-resistant aggregates
during the fibril elongation stage.25,26 It also binds heparin
but the binding of sCLAC to Abeta is influenced by the sta-
bility of its triple helical structure and competition with
heparin binding.25 sCLAC was identified as a component
of senile plaques amyloid (SPs) isolated from the brains
of Alzheimer disease case subjects.24 Amyloid beta (A4)
precursor protein (APP) is cleaved predominantly (about
90%) by a secretase to release soluble protein a (sAPP a)
and slightly (about 10%) by b and g secretases to release
soluble protein b (sAPP b) and Abeta peptide. The accumu-
lation of neurotoxic Abeta peptide leads to amyloid plaque
and Alzheimer disease development.27 sCLAC plays a crit-
ical role in regulating the buildup of Abeta fibrils, and
properly folded sCLAC triple helices were reported to
inhibit Abeta fibril formation in vitro. Once Abeta fibrils
are formed, sCLAC supports their assembly into protease-
resistant aggregates.26,28 None of our case subjects had
any family history of Alzheimer-related phenotype, but
this does not rule out the possibility of the disease devel-
oping later in these individuals.
We investigated the expression of COL25A1 by using
cDNA libraries from commercially available multiple
human adult and fetal tissues (Genemed Synthesis and
Capital Biosciences) and primers specific for COL25A1
(Table S2). In addition, immunohistochemistry (IHC)
was performed to ascertain the tissue distribution of
COL25A1 in E12 and E16 mouse embryos, whole mouse
eye, and human eye muscle. Anti-COL25A1 antibodies
(LS-B664 LifeSpan BioSciences or H00084570-B01, Novus
Biological) were used after ensuring their specificity via
peptide competition assay against COL25A1 full-length re-
combinant protein (H00084570-P01, Novus Biological).
Our cDNA analysis demonstrated that COL25A1 is ubiqui-
tously expressed in different adult and fetal tissues.
COL25A1 was also detected in different parts of mouse
embryos. When cDNA expression was further examined
in differential adult human brain tissues, abundant, 2015
Figure 1. Effect of the p.Gly382Arg Substitution on Protein
Stability
Media from HEK293 cells transfected with either wild-type (WT)
or c.1144G>A containing COL25A1 expression vector were used.
(A) Left: Immunoblot analysis of secreted proteins present in
culture media from untransfected control (UntrC), WT, or
p.Gly382Arg-overexpressing HEK293 cells. Bands corresponding
to sCLAC (~52 kDa) are enriched in WT and p.Gly382Arg-
overexpressing cells but not UntrC. Right: Recombinant sCLAC
was captured with anti-His-tag beads and resolved on SDS-PAGE
prior to performing Ponceau S staining.
(B) Thermal stability of WT and p.Gly382Arg sCLAC. WT
displayed limited proteolytic digestion at 40C and 50C and
was completely digested at higher temperatures whereas the
p.Gly382Arg protein was completely digested at all examined tem-
peratures indicating loss of triple helix stability and folding (data
for temperatures above 50C not shown).expression in the hippocampus and occipital lobe, moder-
ate expression in the frontal lobe and the optic cranial
nerve, and low expression in the left cerebellum were
observed (Figure S3). Moreover, microarray and in situ hy-
bridization data from Allen Brain Atlas database reported
similar COL25A1 expression in the adult human hippo-
campus, frontal lobe, and cerebellum cortex. Interestingly,
the database documented positive expression of COL25A1
in the adult human oculomotor nuclear complex (respon-
sible for extraocular eye and levator palpebrae superioris
muscles innervation) and in the abducens nucleus. Our
cDNA data showed high COL25A1 expression in conjunc-
tive fibroblasts and human fetal and adult whole eye; in
addition, our IHC detected moderate to strong staining
in mouse eye and human eye muscle (Table S4, Figure S4).
These results suggest a functional role for this gene in
different regions of the brain and eye.
Glycine substitutions generally interrupt the unique
collagen’s repetitive pattern (Gly-Pro-X) that is required
for triple helix stability; such substitutions significantly
contribute to pathogenic phenotypes. Recurrence of gly-
cine at every third position dominates proper collagenThe Amertriple helix folding because it is the only amino acid with
a small uncharged functional group that can center the su-
per coiled helix without altering the helix configuration.
Collagens with completely folded triple helices are typi-
cally resistant to trypsin digestion unless the helix is
disrupted via increased temperatures. Peptide model of
collagen, type I, alpha 1 linked to osteogenesis imperfecta
(OI [MIM 166200]) showed that substituting glycine for
arginine decreased the melting temperature, causing
disruptive consequences.29 Our in silico analysis with
both Imutant and Pmut softwares30,31 predicted loss of sta-
bility as a result of the p.Gly382Arg substitution. Because
this change is located within a repetitive (Gly-Pro_X)
stretch and involves the replacement of a glycine for argi-
nine, we examined the sensitivity of recombinant sCLAC
to trypsin digestion at different temperatures to assess
the thermal stability of wild-type and p.Gly382Arg sCLAC.
First we introduced the missense mutation into ready full-
length ORF His/Myc COL25A cDNA clone (OmicsLink
Expression-Ready Clones, Source BioScience) by site-
directed mutagenesis (Quik Change II XL Site-Directed
Mutagenesis Kit, Agilent) according to the manufacturer’s
protocol. After confirming the presence of the mutation
by colony PCR followed by sequencing (Figure S5),
cultured HEK293 cells were transfected with wild-type or
mutant COL25A1 expression vector via FuGENE 6 trans-
fection reagent (Roche) and stable cell lines were selected
in the presence of neomycin. Immunoblotting with His-
tagged antibody conducted on conditioned media from
transfected and untransfected HEK293 cells showed equal
bands for both wild-type and the p.Gly382Arg sCLAC,
indicating that both are expressed and secreted to the
cell culture medium at similar levels (Figure 1A). Condi-
tioned media collected from transfected cells stably
expressing wild-type or p.Gly382Arg sCLAC were heated
at 40C–80C for 5 min and then treated with trypsin for
2 min. The trypsin digests were inactivated and blotted
with anti-His antibody. Limited digestion was observed
for wild-type protein at temperatures up to 50C whereas
the p.Gly382Arg sCLAC was completely digested at all
examined temperatures, suggesting loss of stability and
incorrect folding, which might render the p.Gly382Arg
sCLAC susceptible to proteolysis and disturb its physiolog-
ical functions (Figure 1B). To further explore the effect of
this substitution on sCLAC interaction with sAPP and
Netrin 1 (NTN1, an APP interacting partner), sCLAC was
immunoprecipitated from culture media and the precipi-
tates and fractions of their inputs were probed against
sAPP (Abcam, ab78271) and NTN1 (Abcam, ab126729).
Both wild-type and p.Gly382Arg sCLAC showed similar
interactions with sAPP and NTN1 (Figure S6).
Although the heterozygous c.1489G>Tmutation identi-
fied in both affected and unaffected siblings DRSA1 and
DRSA2 produces a truncated protein, it is plausible that
the wild-type compensates for the deleterious effect of
the truncated allele; therefore, the heterozygous mutation
is less likely to have a pathogenic consequence on its own.ican Journal of Human Genetics 96, 147–152, January 8, 2015 149
Figure 2. Assessment of sCLAC, sAPP,
NTN1, and TUBB3 Levels in DRSA1
Center: Representative immunoblots for
sCLAC (n ¼ 3), sAPP (n ¼ 2), NTN1
(n ¼ 1), and TUBB3 (n ¼ 3) in affected sub-
ject DRSA1 (DRSA1aff), unaffected subject
DRSA2 (DRSA2unaff), and normal control
(NC) (n ¼ 1 for all proteins). DRSA1aff has
diminished levels of sCLAC, low levels of
sAPP, and a slightly decreased level of
TUBB3 compared to DRSA2unaff, whereas
levels of NTN1 were comparable in both
samples. Observed band sizes were between
52 and 76 kDa for sCLAC, sAPP, NTN1, and
TUBB3. Left: Controls from either plasma
or HEK293 lysate/media, referred to as anti-
body controls (AB-Cont), demonstrate that
sAPP, NTN1, and TUBB3 band sizes corre-
spond to those observed in other experi-
ments. Anti-sCLAC antibody was validated
by peptide block. Both b-actin (center)
and albumin (right) were used as internal
controls.In DRSA1, this mutation was accompanied by an intra-
genic copy-number deletion that presumably contributed
to the phenotype. The p.Gly497Ter truncation resulted
in the loss of the C terminus COL3 and NC4 domains of
COL25A1, whereas the CNV results in the loss of the entire
NC2 domain including Abeta peptide/Heparin interaction
site and parts of COL1 and COL2 domains (Figure S2).
Intragenic copy-number deletions that remove part of
the coding region can lead to truncations or a frameshift
creating a premature stop codon and might result in
nonsense-mediated decay (NMD) that probably dimin-
ishes the protein.32 In line with this, our immunoblotting
analysis showed diminished sCLAC in DRSA1 compared to
the unaffected brother DRSA2, strongly suggesting that
loss of function of both alleles is necessary for expression
of the phenotype (Figure 2).
TUBB3 is a neuron-specific component of the cytoskel-
etal microtubules that is abundantly produced during
axon guidance in the nervous system. The encoded protein
is involved in the development of human ocular motor
neurons and in guidance of commissural fibers and
cranial nerves.11,33 Eight distinct heterozygous missense
mutations were reported in TUBB3 in CFEOM3.11 TUBB3
is involved in different pathways and associates with
different protein partners; such associations include the
direct interaction with the DCC complex that participates
in proper axon guidance in the presence of functional APP
and NTN1 (axon guidance tropic cue) and the direct effect
on KIF21A microtubule interactions.11,34,35
In order to investigate the molecular consequences of
the diminished sCLAC, we assessed sAPP, NTN1, and
TUBB3 protein levels by immunoblot analysis in samples
from DRSA1 and DRSA2. NTN1 was detected in plasma
of both siblings whereas sAPP was detected with sharp
band intensity only in plasma of the unaffected sibling
DRSA2. TUBB3 was detected with sharp band intensity in
the unaffected subject DRSA2 compared to weaker band150 The American Journal of Human Genetics 96, 147–152, January 8in the affected sibling DRSA1. Both b-actin and albumin
were included as internal controls (Figure 2). We also
examined the level of KIF21A, which was similar in both
siblings (data not shown). We hypothesize that the trun-
cated COL25A1/sCLAC influences the signaling cascade
involved in axon guidance by affecting sAPP and TUBB3
and probably other axon guidancemolecules during devel-
opment. This hypothesis is supported by the compromised
sAPP and TUBB3 levels observed in this single case subject
and the sustained NTN1 interaction with sCLAC detected
by immunoprecipitation assay.
Col25a1 knockout mice exhibited loss of motor axon
elongation and branching in the muscles, which resulted
in axon degeneration. This effect leads to death due to
respiratory failure, which highlights the regulatory role
for COL25A1 in intramuscular innervation during
development.36 All our case subjects with mutations in
COL25A1 showed variable ophthalmological clinical pre-
sentation with no other systemic defects. Two of the
affected individuals from family A (II.1 and II.2) with mu-
tations in COL25A1were diagnosed with levator palpebrae
muscle dysinnervation (congenital ptosis) of one or both
orbits. The levator palpebrae muscle is normally inner-
vated by the oculomotor nerve (cranial nerve III).2 The
third affected member of family A (II.3) was diagnosed
with dysinnervation to the lateral and/or medial rectus
muscles of both eyes. Themedial rectus muscle is normally
innervated by inferior division of the oculomotor nerve
and the lateral rectus muscle is normally innervated by
the abducens nerve (cranial nerve VI).1 Abnormalities of
guidance and survival of the cranial nerves underlie
different CCDD phenotypes.
Taken together, we identified COL25A1 mutations as a
cause of autosomal-recessive CCDD. Our molecular char-
acterization of the protein and the transcript demonstrated
their presence in human eye muscle and in fetal and adult
brain, respectively. Further assessment of mutations in this, 2015
gene suggests that a defective protein interferes with
molecules involved in axon guidance and might result in
abnormal cytoskeletal microtubule dynamics and atypical
ocular motor neuron development. Further investigations
are necessary to elucidate the possible regulatory effect of
functional COL25A1 on the levels of APP, TUBB3, and
other proteins, including KIF21A, relevant to ocular motor
neuron development.Supplemental Data
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